Johnsson F, Weywadt L, Solhaug J H, Hernqvist H, Bengtsson L
Dept. of Surgery, Lund University Hospital, Sweden.
Scand J Gastroenterol. 1998 Jan;33(1):15-20. doi: 10.1080/00365529850166149.
Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient. The diagnostic value of a treatment test with omeprazole is unclear.
Patients with dyspepsia including heartburn admitted for upper gastrointestinal endoscopy were studied in a prospective, randomized, double-blind Scandinavian multicentre study. Before entry 188 patients were enrolled, and 160 were randomized to 1-week treatment with 20 mg omeprazole twice daily or placebo. Gastro-oesophageal reflux disease (GERD) was defined as reflux oesophagitis Savary-Miller grades II-III at endoscopy or pH < 4 exceeding 4% of the total time at 24-h oesophageal pH-monitoring and was found in 135 patients. The treatment test was considered positive when the patient's symptoms improved during the treatment week compared with the pretreatment day.
The sensitivity in diagnosing reflux disease was 71-81% with omeprazole as a diagnostic test, compared with 36-47% for placebo during treatment days 3-7. The specificity was similar for the two treatment arms during the first days of the study. During the end of the week a larger proportion of the patients with normal endoscopy and pH test responded to omeprazole treatment, giving omeprazole lower specificity than placebo. The investigators' overall evaluation of whether the patient was a responder to the test had a sensitivity of 75% and a specificity of 55% in the omeprazole-treated patients. The corresponding figures in the placebo group were 17% and 92%, respectively.
One week of omeprazole treatment is a simple diagnostic test with a fairly high sensitivity. The specificity is poor owing to the placebo effect and to the lack of a gold standard in diagnosing reflux disease.
胃食管反流症状很常见,目前可用的反流病诊断方法昂贵且让患者感到不适。奥美拉唑治疗试验的诊断价值尚不清楚。
在一项前瞻性、随机、双盲的斯堪的纳维亚多中心研究中,对因消化不良(包括烧心)而接受上消化道内镜检查的患者进行了研究。入组前招募了188名患者,其中160名被随机分为两组,分别接受每日两次20毫克奥美拉唑治疗1周或安慰剂治疗。胃食管反流病(GERD)定义为内镜检查时Savary-Miller分级为II-III级的反流性食管炎,或24小时食管pH监测中pH<4的时间超过总时间的4%,135名患者被诊断为GERD。当患者在治疗周内的症状与治疗前一天相比有所改善时,治疗试验被认为是阳性的。
以奥美拉唑作为诊断试验时,诊断反流病的敏感性为71%-81%,而在治疗第3-7天,安慰剂组的敏感性为36%-47%。在研究的头几天,两个治疗组的特异性相似。在周末时,内镜检查和pH测试正常的患者中,有较大比例对奥美拉唑治疗有反应,这使得奥美拉唑的特异性低于安慰剂。研究人员对患者是否为试验反应者的总体评估中,奥美拉唑治疗组的敏感性为75%,特异性为55%。安慰剂组的相应数字分别为17%和92%。
一周的奥美拉唑治疗是一种简单的诊断试验,敏感性相当高。由于安慰剂效应以及缺乏诊断反流病的金标准,其特异性较差。